351 related articles for article (PubMed ID: 33296125)
1. Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.
van Brummelen EMJ; Huijberts S; van Herpen C; Desar I; Opdam F; van Geel R; Marchetti S; Steeghs N; Monkhorst K; Thijssen B; Rosing H; Huitema A; Beijnen J; Bernards R; Schellens J
Oncologist; 2021 Apr; 26(4):290-e545. PubMed ID: 33296125
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
van Geel RMJM; van Brummelen EMJ; Eskens FALM; Huijberts SCFA; de Vos FYFL; Lolkema MPJK; Devriese LA; Opdam FL; Marchetti S; Steeghs N; Monkhorst K; Thijssen B; Rosing H; Huitema ADR; Beijnen JH; Bernards R; Schellens JHM
Br J Cancer; 2020 Apr; 122(8):1166-1174. PubMed ID: 32147669
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Huijberts SCFA; van Geel RMJM; van Brummelen EMJ; Opdam FL; Marchetti S; Steeghs N; Pulleman S; Thijssen B; Rosing H; Monkhorst K; Huitema ADR; Beijnen JH; Bernards R; Schellens JHM
Cancer Chemother Pharmacol; 2020 May; 85(5):917-930. PubMed ID: 32274564
[TBL] [Abstract][Full Text] [Related]
4. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
Deming DA; Cavalcante LL; Lubner SJ; Mulkerin DL; LoConte NK; Eickhoff JC; Kolesar JM; Fioravanti S; Greten TF; Compton K; Doyle AG; Wilding G; Duffy A; Liu G
Invest New Drugs; 2016 Apr; 34(2):168-75. PubMed ID: 26666244
[TBL] [Abstract][Full Text] [Related]
6. Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.
Melosky B; Bradbury P; Tu D; Florescu M; Reiman A; Nicholas G; Basappa N; Rothenstein J; Goffin JR; Laurie SA; Wheatley-Price P; Leighl N; Goss G; Reaume MN; Butts C; Murray N; Card C; Ko J; Blais N; Gray S; Lui H; Brown-Walker P; Kaurah P; Prentice LM; Seymour L
Lung Cancer; 2019 Jul; 133():48-55. PubMed ID: 31200828
[TBL] [Abstract][Full Text] [Related]
7. SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.
Soria JC; Fülöp A; Maciel C; Fischer JR; Girotto G; Lago S; Smit E; Ostoros G; Eberhardt WEE; Lishkovska P; Lovick S; Mariani G; McKeown A; Kilgour E; Smith P; Bowen K; Kohlmann A; Carlile DJ; Jänne PA
Ann Oncol; 2017 Dec; 28(12):3028-3036. PubMed ID: 29045535
[TBL] [Abstract][Full Text] [Related]
8. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
Jänne PA; Shaw AT; Pereira JR; Jeannin G; Vansteenkiste J; Barrios C; Franke FA; Grinsted L; Zazulina V; Smith P; Smith I; Crinò L
Lancet Oncol; 2013 Jan; 14(1):38-47. PubMed ID: 23200175
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in
da Silva-Oliveira RJ; Gomes INF; da Silva LS; Lengert AVH; Laus AC; Melendez ME; Munari CC; Cury FP; Longato GB; Reis RM
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887120
[TBL] [Abstract][Full Text] [Related]
10. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
Carter CA; Rajan A; Keen C; Szabo E; Khozin S; Thomas A; Brzezniak C; Guha U; Doyle LA; Steinberg SM; Xi L; Raffeld M; Tomita Y; Lee MJ; Lee S; Trepel JB; Reckamp KL; Koehler S; Gitlitz B; Salgia R; Gandara D; Vokes E; Giaccone G
Ann Oncol; 2016 Apr; 27(4):693-9. PubMed ID: 26802155
[TBL] [Abstract][Full Text] [Related]
11. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
Oxnard GR; Yang JC; Yu H; Kim SW; Saka H; Horn L; Goto K; Ohe Y; Mann H; Thress KS; Frigault MM; Vishwanathan K; Ghiorghiu D; Ramalingam SS; Ahn MJ
Ann Oncol; 2020 Apr; 31(4):507-516. PubMed ID: 32139298
[TBL] [Abstract][Full Text] [Related]
12. Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
Jänne PA; van den Heuvel MM; Barlesi F; Cobo M; Mazieres J; Crinò L; Orlov S; Blackhall F; Wolf J; Garrido P; Poltoratskiy A; Mariani G; Ghiorghiu D; Kilgour E; Smith P; Kohlmann A; Carlile DJ; Lawrence D; Bowen K; Vansteenkiste J
JAMA; 2017 May; 317(18):1844-1853. PubMed ID: 28492898
[TBL] [Abstract][Full Text] [Related]
13. Selumetinib for the treatment of non-small cell lung cancer.
Casaluce F; Sgambato A; Maione P; Sacco PC; Santabarbara G; Gridelli C
Expert Opin Investig Drugs; 2017 Aug; 26(8):973-984. PubMed ID: 28675058
[TBL] [Abstract][Full Text] [Related]
14. Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1).
Jänne PA; Mann H; Ghiorghiu D
Clin Lung Cancer; 2016 Mar; 17(2):e1-4. PubMed ID: 26837474
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.
Hochster HS; Uboha N; Messersmith W; Gold PJ; ONeil BH; Cohen D; Denlinger C; Cohen S; Leichman CG; Leichman L; Lenz HJ
Cancer Chemother Pharmacol; 2015 Jan; 75(1):17-23. PubMed ID: 25322874
[TBL] [Abstract][Full Text] [Related]
16. Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Shapiro GI; LoRusso P; Kwak E; Pandya S; Rudin CM; Kurkjian C; Cleary JM; Pilat MJ; Jones S; de Crespigny A; Fredrickson J; Musib L; Yan Y; Wongchenko M; Hsieh HJ; Gates MR; Chan IT; Bendell J
Invest New Drugs; 2020 Apr; 38(2):419-432. PubMed ID: 31020608
[TBL] [Abstract][Full Text] [Related]
17. Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC.
Paolo M; Assunta S; Antonio R; Claudia SP; Anna BM; Clorinda S; Francesca C; Fortunato C; Cesare G
Rev Recent Clin Trials; 2013 Jun; 8(2):93-100. PubMed ID: 24063423
[TBL] [Abstract][Full Text] [Related]
18. A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Moran T; Palmero R; Provencio M; Insa A; Majem M; Reguart N; Bosch-Barrera J; Isla D; Costa EC; Lee C; Puig M; Kraemer S; Schnell D; Rosell R
Lung Cancer; 2017 Jun; 108():154-160. PubMed ID: 28625629
[TBL] [Abstract][Full Text] [Related]
19. Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer.
Krishnamurthy A; Dasari A; Noonan AM; Mehnert JM; Lockhart AC; Leong S; Capasso A; Stein MN; Sanoff HK; Lee JJ; Hansen A; Malhotra U; Rippke S; Gustafson DL; Pitts TM; Ellison K; Davis SL; Messersmith WA; Eckhardt SG; Lieu CH
Cancer Res; 2018 Sep; 78(18):5398-5407. PubMed ID: 30042150
[TBL] [Abstract][Full Text] [Related]
20. Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation.
Imyanitov EN; Levchenko EV; Kuligina ES; Orlov SV
Expert Opin Pharmacother; 2020 Nov; 21(16):1943-1953. PubMed ID: 32880495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
